Kymera Investor Day Presentation Deck

• No SAEs Treatment-related AEs observed only in SAD 5 and SAD 6; all were self-limiting and resolved ● KYMERA No treatment-related AEs in SAD 7 • No significant ECG changes Blinded SAD Safety Summary n=8 per cohort (6 drug/2 placebo) ©2021 KYMERA THERAPEUTICS, INC. * Possibly or Probably Treatment-Related AES* (>1 Subject) #Subjects Severity AE Term Headache Nausea per investigator assessment 4 2 KYMERA R&D DAY - December 16th, 2021 Moderate (x2) Mild (x2) Mild (x2) Cohort SAD 5, SAD 6 SAD 5 SAD 6 PAGE 32

View entire presentation